1. Soulie P, Gamelin E, Eder J (2003) A dose finding study of an oral antiangiogenesis inhibitor, NM-3 safety profile and effects on surrogate markers with once-daily dosing. Abstract No. 777. Proc Amer Soc Clin Oncol
2. Bonate P, Eder J, Soulie P (2003) Pharmacokinetics of a new antiangiogenic isocoumarin derivative, NM-3 in two oral once a day-dose schedules with escalating doses, Abstract No. 537. Proc Amer Soc Clin Oncol 22:132
3. Nakashima T, Hirano S, Agata N et al (1999) Inhibition of angiogenesis by a new isocoumarin, NM-3. J Antibiot 52:426–428
4. Salloum R, Jaskowiak N, Mauceri H et al (2000) NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res 60:6958–6963
5. Agata N, Tsuchiya A, Issihiki K (2001) NM-3, a novel orally bioavilable antiangeiogenic agents suppresses hypoxia-induced vascular endothelial growth factor (VEGF) in human fibroblasts and tumor cells. Proc AACR 41:587